Compare ACADIA Pharmaceuticals Inc. (ACAD) vs YieldMax TSLA Option Income Strategy ETF (TSLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs YieldMax TSLA Option Income Strategy ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.07B), while YieldMax TSLA Option Income Strategy ETF trades at $21.94. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, YieldMax TSLA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| ACAD | TSLY | |
|---|---|---|
Market Cap | $5.07B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $29.41 | $48.25 |
52-Week Low | $20.06 | $20.49 |
Enterprise Value | $4.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TSLY trades at $21.55, up 1.03% today, with a bearish technical signal from moving averages and mixed oscillators. The ETF maintains a high dividend yield strategy, with recent weekly distributions averaging around $0.28 per share. Support and resistance levels are tightly clustered near the current price, indicating limited near-term price movement potential.
The outlook for TSLY is cautious due to capped upside from its option income structure and dependence on Tesla's volatility. Risks include missed participation in Tesla rallies and high distribution volatility. Analyst sentiment has shifted to neutral, reflecting concerns over sustainable yield and growth constraints.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About YieldMax TSLA Option Income Strategy ETF
TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Read more on TSLY →
